Weight Loss Drug CagriSema Fails to Meet Non-Inferiority Goal

Novo Nordisk stock fell 10% after drug failed.
CagriSema didn’t meet non-inferiority target for weight loss.
Drug compared to Eli Lilly’s tirzepatide over 84 weeks.
1 day ago
Daily Digest
Privacy Policy
Terms of Service
Contact Us
Copyright © 2026 Minimalist News. All Rights Reserved.